ProQR (PRQR)
NASDAQ:PRQR
Want to see PRQR full AI Analyst Report?
Top Page
ProQR
(NASDAQ:PRQR)
Select Model
Select Model
Rating:49Neutral
Price Target:
$2.00
▲(0.50% Upside)
Action:ReiteratedDate:04/10/26
The score is held back primarily by weak financial performance (persistent losses and renewed heavy cash burn) and a negative P/E that underscores lack of profitability. Technicals provide some support due to improving price momentum above key moving averages.
Positive Factors
Platform & Pipeline Expansion
ProQR's expansion of the Axiomer pipeline with multiple development candidates and planned catalysts through 2027 strengthens its long-term growth runway. A broader pipeline increases 'shots on goal', diversifies clinical risk across indications, and supports sustained R&D value creation if technical validation continues.
Negative Factors
Persistent Losses & Cash Burn
Sustained operating and net losses with deep negative operating and free cash flow across recent years highlight an entrenched cash-burn biotech profile. This structural funding demand increases reliance on external financing, which can dilute shareholders or constrain strategic flexibility if burn does not moderate.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform & Pipeline Expansion
ProQR's expansion of the Axiomer pipeline with multiple development candidates and planned catalysts through 2027 strengthens its long-term growth runway. A broader pipeline increases 'shots on goal', diversifies clinical risk across indications, and supports sustained R&D value creation if technical validation continues.
Read all positive factors
ProQR (PRQR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$209.67M
Dividend YieldN/A
Average Volume (3M)534.76K
Price to Earnings (P/E)―
Beta (1Y)2.08
Revenue Growth-11.99%
EPS Growth-42.04%
CountryUS
Employees166
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.09
Shares Outstanding105,361,060
10 Day Avg. Volume796,312
30 Day Avg. Volume534,757
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)3.67
Price to Sales (P/S)11.85
P/FCF Ratio-3.50
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue5.41
Enterprise Value/Gross Profit5.65
Enterprise Value/Ebitda-2.13
Forecast
1Y Price Target
$8.20Price Target Upside312.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$23.20M
ProQR Business Overview & Revenue Model
Company Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate tri...
How the Company Makes Money
null...
ProQR Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
52
Neutral
Cash Flow
31
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 15.28M | 18.91M | 6.51M | 3.59M | 1.33M |
| Gross Profit | 12.68M | 18.91M | 6.51M | 3.59M | 1.33M |
| EBITDA | -39.56M | -24.12M | -24.10M | -56.46M | -54.95M |
| Net Income | -40.52M | -27.76M | -28.12M | -64.42M | -60.74M |
Balance Sheet | |||||
| Total Assets | 112.71M | 167.96M | 152.31M | 171.32M | 209.58M |
| Cash, Cash Equivalents and Short-Term Investments | 92.37M | 149.41M | 131.37M | 94.78M | 187.52M |
| Total Debt | 13.99M | 17.22M | 21.80M | 21.97M | 60.37M |
| Total Liabilities | 63.36M | 79.40M | 106.59M | 104.64M | 96.35M |
| Stockholders Equity | 49.35M | 88.56M | 45.72M | 67.06M | 113.83M |
Cash Flow | |||||
| Free Cash Flow | -51.69M | -37.81M | 20.18M | -69.22M | -26.50M |
| Operating Cash Flow | -50.71M | -36.39M | 21.55M | -68.51M | -26.01M |
| Investing Cash Flow | -979.74K | -4.07M | 4.28M | -702.00K | -425.00K |
| Financing Cash Flow | -1.76M | 70.28M | -2.27M | -30.89M | 136.83M |
ProQR Technical Analysis
Positive
1.99
Price Trends
1.65
Positive
1.81
Positive
2.05
Negative
Market Momentum
0.09
Negative
60.74
Neutral
66.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRQR, the sentiment is Positive. The current price of 1.99 is above the 20-day moving average (MA) of 1.72, above the 50-day MA of 1.65, and below the 200-day MA of 2.05, indicating a neutral trend. The MACD of 0.09 indicates Negative momentum. The RSI at 60.74 is Neutral, neither overbought nor oversold. The STOCH value of 66.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRQR.
ProQR Risk Analysis
ProQR disclosed 81 risk factors in its most recent earnings report. ProQR reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ProQR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $468.47M | -1.84 | -46.34% | ― | ― | 14.33% | |
55 Neutral | $214.28M | -3.25 | -22.37% | ― | 3.36% | 5.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $223.54M | -3.23 | -90.51% | ― | -17.87% | 14.42% | |
49 Neutral | $209.67M | -5.01 | -65.10% | ― | -11.99% | -42.04% | |
48 Neutral | $180.37M | -10.73 | 304.91% | ― | 12.60% | 58.23% |
* Healthcare Sector Average
PRQR
ProQR
1.84
0.52
39.39%
CDXS
Codexis
2.62
0.49
23.00%
HRTX
Heron Therapeutics
1.05
-0.88
-45.60%
TLSA
Tiziana Life Sciences
1.21
0.08
7.08%
AVIR
Atea Pharmaceuticals
5.71
2.85
99.65%
OABI
OmniAb
1.55
-0.28
-15.30%
ProQR Corporate Events
ProQR Details Axiomer Pipeline Expansion and New Liver and Genetic Disease Programs
Apr 8, 2026
On April 8, 2026, ProQR Therapeutics hosted a virtual analyst and investor event titled “Expanding the Axiomer RNA Editing Opportunity Beyond AX-0810” to outline progress across its RNA-editing pipeline. Management highlighted AX-0810 ...
ProQR Partners with Ginkgo Bioworks, Launches AI Advisory Board to Drive Axiomer RNA Drug Discovery
Apr 8, 2026
ProQR Therapeutics, a Netherlands-based RNA biotech specializing in Axiomer RNA base-editing therapies, is expanding its technology platform to target a broad range of rare and common diseases by correcting RNA mutations or modulating protein expr...
ProQR Sets April 8 Virtual Investor Event to Spotlight Axiomer RNA Editing Pipeline
Mar 25, 2026
On March 25, 2026, ProQR Therapeutics announced it will host a virtual Investor and Analyst Event on April 8, 2026, to showcase its expanding pipeline of RNA editing therapies built on the Axiomer platform. The event, titled “Expanding the A...
ProQR Posts 2025 Results as Axiomer RNA Editing Pipeline Advances and Cash Runway Extends to Mid-2027
Mar 12, 2026
On March 12, 2026, ProQR reported its operating and financial results for the year ended Dec. 31, 2025, highlighting progress on lead candidate AX-0810 for cholestatic diseases, which is in an ongoing Phase 1 multiple-dose study in healthy volunte...
ProQR Therapeutics Plans Board Changes as Co-Founder and Director Exit at 2026 AGM
Feb 9, 2026
On February 9, 2026, ProQR Therapeutics announced planned changes to its board of directors, with co-founder Dinko Valerio and director Alison Lawton set to rotate off the board at the company’s 2026 Annual General Meeting as their terms con...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.